Crossmark

The benefit of macrolide therapy in patients with pneumococcal pneumonia is only present in patients with bacteremia

Crossref DOI link: https://doi.org/10.1016/j.pulmoe.2022.08.003

Published Print: 2023-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Gonçalves-Pereira, J. http://orcid.org/0000-0002-7538-3777
Costa, L.

Silva, I.

Simões, A. http://orcid.org/0000-0001-6714-8585
Froes, F.

Mergulhão, P.

Varela Ramos, P.

Leal, D.

Alves, R.

Custódio, M.

Gomes, A.
Funding

Funding for this research was provided by:

Merck (60150)

Merck Sharp and Dohme
License Information

Text and Data Mining valid from 2023-05-01

Text and Data Mining valid from 2023-05-01

Version of Record valid from 2022-08-13
More Information

This article is maintained by: Elsevier

Article Title: The benefit of macrolide therapy in patients with pneumococcal pneumonia is only present in patients with bacteremia

Journal Title: Pulmonology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.pulmoe.2022.08.003

Content Type: simple-article

Copyright: © 2022 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U.